IL198930A0 - Non-standard amino acid conjugates of amphetamine and processes for making and using the same - Google Patents
Non-standard amino acid conjugates of amphetamine and processes for making and using the sameInfo
- Publication number
- IL198930A0 IL198930A0 IL198930A IL19893009A IL198930A0 IL 198930 A0 IL198930 A0 IL 198930A0 IL 198930 A IL198930 A IL 198930A IL 19893009 A IL19893009 A IL 19893009A IL 198930 A0 IL198930 A0 IL 198930A0
- Authority
- IL
- Israel
- Prior art keywords
- amphetamine
- making
- amino acid
- same
- standard amino
- Prior art date
Links
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 title abstract 2
- 229940025084 amphetamine Drugs 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86937506P | 2006-12-11 | 2006-12-11 | |
| PCT/US2007/087028 WO2008073918A1 (en) | 2006-12-11 | 2007-12-10 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL198930A0 true IL198930A0 (en) | 2010-02-17 |
Family
ID=39512105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL198930A IL198930A0 (en) | 2006-12-11 | 2009-05-25 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7776917B2 (OSRAM) |
| EP (1) | EP2101571B1 (OSRAM) |
| JP (1) | JP2010512413A (OSRAM) |
| CN (1) | CN101594778A (OSRAM) |
| AT (1) | ATE509622T1 (OSRAM) |
| AU (1) | AU2007333105A1 (OSRAM) |
| BR (1) | BRPI0720105A2 (OSRAM) |
| CA (1) | CA2672138A1 (OSRAM) |
| ES (1) | ES2364865T3 (OSRAM) |
| IL (1) | IL198930A0 (OSRAM) |
| WO (1) | WO2008073918A1 (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
| EP2018160B1 (en) | 2006-03-16 | 2011-12-14 | Tris Pharma, Inc. | Modified release formulations containing drug-ion exchange resin complexes |
| EP2101571B1 (en) | 2006-12-11 | 2011-05-18 | Kempharm, Inc. | Ornithine conjugates of amphetamine and processes for making and using the same |
| EP2433654A3 (en) | 2007-02-08 | 2013-05-15 | Kempharm, Inc. | Citrulline and homocitrulline prodrugs of amphetamines and processes for making and using the same |
| DE102007037478B3 (de) | 2007-08-08 | 2008-04-30 | Leifheit Ag | Wäschetrockenständer |
| US8614346B2 (en) | 2009-06-19 | 2013-12-24 | Cambrex Charles City, Inc. | Methods and compositions for preparation of amphetamine conjugates and salts thereof |
| ES2710617T3 (es) | 2010-04-21 | 2019-04-26 | Signature Therapeutics Inc | Composiciones que comprenden profármacos de anfetamina escindibles enzimáticamente e inhibidores de los mismos |
| US8779191B2 (en) | 2010-12-20 | 2014-07-15 | Cambrex Charles City, Inc. | Methods and compositions for preparing lisdexamfetamine and salts thereof |
| CA3123900A1 (en) * | 2011-07-28 | 2013-01-31 | Kempharm Inc. | Methylphenidate-prodrugs, processes of making and using the same |
| US20140171510A1 (en) * | 2011-07-29 | 2014-06-19 | Shire Llc | Homoarginine prodrugs and/or conjugates of amphetamine and other stimulants and processes for making and using the same |
| AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| WO2014002039A1 (en) * | 2012-06-27 | 2014-01-03 | Shire Ag | Amphetamine prodrugs |
| WO2014058742A1 (en) | 2012-10-09 | 2014-04-17 | Sears Douglas | Therapeutic treatment |
| US10314839B2 (en) | 2014-10-20 | 2019-06-11 | Elysium Therapeutics, Inc. | Diversion-resistant opioid formulations |
| US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| GB2556817B (en) | 2015-10-01 | 2019-11-06 | Elysium Therapeutics Inc | Polysubunit opioid prodrugs resistant to overdose and abuse |
| US10335406B2 (en) | 2015-10-01 | 2019-07-02 | Elysium Therapeutics, Inc. | Opioid compositions resistant to overdose and abuse |
| JP2020500220A (ja) | 2016-11-15 | 2020-01-09 | クラリア ファーマ ホールディング エービー | 医薬製剤 |
| CN110234636B (zh) | 2016-12-11 | 2022-09-20 | 坎普哈姆公司 | 包含哌醋甲酯前药的组合物，其制造和使用方法 |
| WO2018160178A1 (en) | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof |
| EP3595663A4 (en) | 2017-03-17 | 2021-01-13 | Elysium Therapeutics, Inc. | MULTI-UNIT OPIOID MEDICINES RESISTANT TO OVERDOSE AND ABUSE |
| US20200155687A1 (en) * | 2017-04-10 | 2020-05-21 | Shire Pharmaceuticals Inc. | Methods of treatment using an amphetamine prodrug |
| GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| EP3692042A1 (en) * | 2017-10-06 | 2020-08-12 | Instituto de Medicina Molecular João Lobo Antunes | Treatment of obesity-related conditions |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| WO2019199731A1 (en) * | 2018-04-10 | 2019-10-17 | Shire Pharmaceuticals Inc. | Amphetamine prodrug and crystalline froms thereof |
| GB201808462D0 (en) * | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| WO2020181000A1 (en) * | 2019-03-06 | 2020-09-10 | Ensysce Biosciences, Inc. | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof |
| CN113993523A (zh) | 2019-04-17 | 2022-01-28 | 指南针探路者有限公司 | 用赛洛西宾治疗抑郁症和其他各种病症 |
| AU2020402994A1 (en) | 2019-12-11 | 2022-06-23 | Inspirna, Inc. | Methods of treating cancer |
| TW202309004A (zh) * | 2021-08-24 | 2023-03-01 | 美商精神醫學公司 | 藉由使用受控和非受控中間體獲取ｍｄｍａ前驅藥之合成途徑 |
| MX2024003466A (es) | 2021-09-29 | 2024-06-04 | Ensysce Biosciences Inc | Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos. |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL198169A (OSRAM) * | 1954-06-28 | |||
| US2881113A (en) | 1957-01-29 | 1959-04-07 | Ortho Pharma Corp | Therapeutically active compositions containing amphetamines |
| US2892753A (en) * | 1957-02-26 | 1959-06-30 | Boehringer Sohn Ingelheim | Central nervous system stimulant |
| DE1493824A1 (de) | 1964-01-27 | 1969-05-22 | Hoffmann La Roche | Verfahren zur Herstellung von Aminocarbonsaeureamiden |
| ES2412409T3 (es) | 1997-12-22 | 2013-07-11 | Euro-Celtique S.A. | Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo |
| AU6528400A (en) | 1999-08-23 | 2001-03-19 | David M. Ockert | Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms |
| EP1292307A2 (en) | 2000-06-09 | 2003-03-19 | The Regents of The University of California | Method of treating pain using nalbuphine and opioid antagonists |
| US6417184B1 (en) | 2000-09-19 | 2002-07-09 | David M. Ockert | Triple drug therapy for the treatment and prevention of acute or chronic pain |
| EP2319540A1 (en) * | 2002-02-22 | 2011-05-11 | Shire LLC | Sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| US7105486B2 (en) * | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| WO2004091499A2 (en) * | 2003-04-09 | 2004-10-28 | Neose Technologies, Inc. | Intracellular formation of peptide conjugates |
| NZ544162A (en) | 2003-05-29 | 2008-09-26 | Shire Llc | Abuse resistant amphetamine compounds |
| US20080234206A1 (en) | 2005-09-13 | 2008-09-25 | Shire Llc | Prodrugs of Phentermine |
| EP2101571B1 (en) * | 2006-12-11 | 2011-05-18 | Kempharm, Inc. | Ornithine conjugates of amphetamine and processes for making and using the same |
| EP2433654A3 (en) * | 2007-02-08 | 2013-05-15 | Kempharm, Inc. | Citrulline and homocitrulline prodrugs of amphetamines and processes for making and using the same |
-
2007
- 2007-12-10 EP EP07869098A patent/EP2101571B1/en not_active Not-in-force
- 2007-12-10 US US11/953,668 patent/US7776917B2/en active Active
- 2007-12-10 CN CNA2007800458802A patent/CN101594778A/zh active Pending
- 2007-12-10 WO PCT/US2007/087028 patent/WO2008073918A1/en not_active Ceased
- 2007-12-10 JP JP2009541507A patent/JP2010512413A/ja not_active Withdrawn
- 2007-12-10 CA CA002672138A patent/CA2672138A1/en not_active Abandoned
- 2007-12-10 BR BRPI0720105-2A2A patent/BRPI0720105A2/pt not_active IP Right Cessation
- 2007-12-10 AU AU2007333105A patent/AU2007333105A1/en not_active Abandoned
- 2007-12-10 ES ES07869098T patent/ES2364865T3/es active Active
- 2007-12-10 AT AT07869098T patent/ATE509622T1/de not_active IP Right Cessation
-
2009
- 2009-05-25 IL IL198930A patent/IL198930A0/en unknown
- 2009-05-28 US US12/473,903 patent/US20090234018A1/en not_active Abandoned
-
2010
- 2010-07-26 US US12/843,169 patent/US8101661B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007333105A1 (en) | 2008-06-19 |
| EP2101571B1 (en) | 2011-05-18 |
| US20080139653A1 (en) | 2008-06-12 |
| US20100292336A1 (en) | 2010-11-18 |
| BRPI0720105A2 (pt) | 2014-10-07 |
| ES2364865T3 (es) | 2011-09-15 |
| JP2010512413A (ja) | 2010-04-22 |
| CN101594778A (zh) | 2009-12-02 |
| US7776917B2 (en) | 2010-08-17 |
| EP2101571A4 (en) | 2010-01-13 |
| WO2008073918A1 (en) | 2008-06-19 |
| US20090234018A1 (en) | 2009-09-17 |
| ATE509622T1 (de) | 2011-06-15 |
| EP2101571A1 (en) | 2009-09-23 |
| US8101661B2 (en) | 2012-01-24 |
| HK1131518A1 (en) | 2010-01-29 |
| CA2672138A1 (en) | 2008-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL198930A0 (en) | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | |
| WO2008098151A3 (en) | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same | |
| WO2008082613A3 (en) | Factor ix moiety-polymer conjugates having a releasable linkage | |
| AP2414A (en) | Fungicidal aqueous compositions for seed treatment. | |
| WO2007093627A3 (de) | Biozide zusammensetzung | |
| WO2010069532A8 (en) | Antibodies against human angiopoietin 2 | |
| WO2007146965A3 (en) | Compounds for the treatment of periodontal disease | |
| WO2008001101A3 (en) | Pharmaceutical combinations | |
| WO2007022535A3 (en) | Prodrugs of active agents | |
| WO2008019395A3 (en) | Compounds for improving learning and memory | |
| WO2007093529A3 (de) | Heteroaroylsubstituierte alanine | |
| WO2008017346A3 (de) | Ascorbinsäurederivate, verwendung zur funktionalisierung von matrices | |
| WO2008059370A8 (en) | Substituted bicyclocarboxyamide compounds | |
| WO2006082523A3 (en) | Pharmaceutical sustained release composition of metformin | |
| TW200621313A (en) | Pharmaceutical compositions | |
| WO2008050199A3 (en) | Substituted phenylmethyl bicyclocarboxyamide compounds | |
| EP1908349A3 (en) | Microbicidal preparations based on 1,2-benzisothiazolin-3-one | |
| WO2009055289A3 (en) | Therapeutic substituted lactams | |
| WO2007022956A3 (en) | Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent | |
| TW200731974A (en) | Transdermal system for verenicline | |
| WO2008051539A3 (en) | Processes for preparing palonosetron salts | |
| WO2007133184A3 (en) | Polypeptides and biosynthetic pathways for the production of stereoisomers of monatin and their precursors | |
| WO2008073863A3 (en) | Preparation and utility of substituted allylamines | |
| WO2007125521A3 (en) | Polymorphic form of zoledronic acid and processes for their preparation | |
| WO2007100668A3 (en) | Antidepressant prodrugs |